Bladder cancer

UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa

Last updated: 14.10.2024

Solve cases and receive feedback

Case 1 - ECOG PS 1, GFR 40 ml/min

Case 2 - Progression 5 mo after adjuvant GC

Case 3 - PR after 12 cycles enfortumab vedotin + pembrolizumab

Case 4 - Complete response after first-line GC

Case 5 - ECOG PS 1, GFR 90 ml/min

Case 6 - Progression while on adjuvant nivolumab

Case 7 - ECOG PS 2, GFR 25 ml/min, grade 3 neuropathy

Case 8 - Complete response after 6 cycles of GC + nivolumab

Case 9 - Progression 15 mo after NAC

Case 10 - Stable disease after first-line GC

Case 11 - Progression 5 mo after NAC while on adjuvant nivolumab

Follow a course and earn CME credits

Earn CME credits by running a case series and completing an assessment. Many topics available for various disease areas. And all for free!

Start a course